Literature DB >> 31778597

Characteristics of aeromedical transport, both interhospital and directly from the scene of the incident, in patients with acute myocardial infarction or acute trauma between 2011-2016 in Poland: A case-control study.

Arkadiusz Wejnarski1, Piotr Leszczyński1, Stanisław Świeżewski2, Marcin Podgórski2, Michał M Farkowski3, Maciej Sterliński4, Mariusz Panczyk5, Joanna Gotlib5, Daniel Rabczenko6, Robert Gałązkowski2.   

Abstract

BACKGROUND: Patients with acute myocardial infarction (AMI) or acute trauma (AT) are transported by air to save time. Helicopter Emergency Medical Service (HEMS) provides both flights to and from the emergency scene, as well as interhospital transport (interHtransport).
OBJECTIVES: The objective of this study was to compare aeromedical transport and HEMS missions of AMI and AT patients regarding safety, medical procedures and the length of flights.
MATERIAL AND METHODS: This is a case-control study analyzing the medical history records of AMI and AT patients transported between hospitals and from the scene identified using ICD-10 codes. Research of customary data (age, sex and general health status measured with Glasgow Coma Scale (GCS) and Revised Trauma Score (RTS)) was performed.
RESULTS: There were 48,555 flights in the years 2011-2016, of which 7,645 (15.7%) were interhospital (19% AMI and 12% AT). Out of these, 40,910 (84.3%) HEMS missions were to patients on the scene (10% AMI and 13% AT). No fatalities were noted. The AMI GCS score was higher than in AT patients: 15.0 vs 14.0, respectively. The medical procedures during transport of AMI patients between hospitals and from the scene were the following: cardiopulmonary resuscitation (CPR): 6 vs 73 cases (p < 0.001); oxygen therapy: 41.1% vs 50.2%, respectively. The median distance was 59.4 km vs 52.1 km (p < 0.001), while median flight time was 45.0 min vs 38.0 min (p < 0.001), respectively. Regarding AT patients, the procedures performed (during interhospital and from the scene transport) were the following: CPR: 5 vs 244 cases (p < 0.001); intubation: 10.7% vs 17.3% (p < 0.001); sedation: 50.1% vs 24.3% (p < 0.001); oxygen therapy: 17.6% vs 36.6% (p < 0.001); spinal board: 17.1% vs 66% (p < 0.001); cervical collar: 15.9% vs 63.4% (p < 0.001), respectively. Interhospital transport and HEMS mission median flight distance was 135.9 km vs 56.3 km (p < 0.001), while median flight time was 66.0 min vs 45.0 min (p < 0.001), respectively.
CONCLUSIONS: Aeromedical transport is safe and very rarely requires resuscitation during the flight. The long distances of flights and time required can reflect the scarcity of trauma centers (TCs) compared to cardiovascular wards. The location of hemodynamic centers in Poland is optimal.

Entities:  

Keywords:  Helicopter Emergency Medical Service; acute myocardial infarction; aeromedical transport; patient with trauma

Mesh:

Year:  2019        PMID: 31778597     DOI: 10.17219/acem/109456

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  3 in total

1.  Effectiveness of LODS, OASIS, and SAPS II to predict in-hospital mortality for intensive care patients with ST elevation myocardial infarction.

Authors:  Liang Wang; Zhengwei Zhang; Tianyang Hu
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

2.  Impact of COVID-19 Pandemic on Quality of Health Services Provided by Emergency Medical Services and Emergency Departments in the Opinion of Patients: Pilot Study.

Authors:  Piotr Konrad Leszczyński; Paulina Sobolewska; Bożena Muraczyńska; Paulina Gryz; Adam Kwapisz
Journal:  Int J Environ Res Public Health       Date:  2022-01-22       Impact factor: 3.390

3.  Neonatal Transport in the Practice of the Crews of the Polish Medical Air Rescue: A Retrospective Analysis.

Authors:  Ewa Rzońca; Stanisław Paweł Świeżewski; Robert Gałązkowski; Agnieszka Bień; Arkadiusz Kosowski; Piotr Leszczyński; Patryk Rzońca
Journal:  Int J Environ Res Public Health       Date:  2020-01-22       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.